Intevac, Inc. (Nasdaq: IVAC) has engaged Houlihan Lokey Capital, Inc. as an investment banking firm to provide guidance and strategic advice to the company's management and board of directors regarding strategic options to maximize stockholder value.

Due to challenges within the hard disk drive (HDD) industry, Intevac faced an unprecedented setback with the cancellation of $54 million in 200 Lean system orders. Nigel Hunton, the president and CEO, acknowledged the impact of these challenges.

In light of recent developments, Intevac has revised its full-year 2023 revenue guidance. The company now expects revenue to be in the range of $43 million to $48 million, surpassing the consensus estimate of $37.29 million for the period.

$IVAC is currently trading at $4.00 in after-hours, reflecting a decline of $0.30 (-6.98%) following the announcement.

Agile Therapeutics, Inc. (Nasdaq: AGRX) has partnered with vitaCare Prescription Services, a subsidiary of GoodRx, to enhance patient access to Twirla, a once-weekly combined hormonal contraceptive patch containing levonorgestrel and ethinyl estradiol. This collaboration aims to overcome access barriers and bolster Twirla's presence in the retail channel. 

The Company's Chief Commercial Officer, Amy Welsh, expressed optimism about reaching new patients who previously faced barriers while ensuring existing patients continue their therapy. Agile Therapeutics plans to expand its commercial reach to achieve key financial goals for 2023, including positive cash flow and net revenue in the range of $25-$30 million.

Twirla is indicated for use by women of reproductive potential as a method of contraception, provided they have a body mass index (BMI) below 30 kg/m2 and require a combined hormonal contraceptive.

Currently, $AGRX is trading in after-hours at $5.28, up $1.69 (+47.08%)

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)